智通财经获悉，瑞士竞争委员会(COMCO)周四表示，终止对诺华制药公司(NVS.US)的调查，不产生任何后果。该委员目的是确定诺华公司是否有意通过提起各种专利侵权诉讼来非法保护其一种皮肤病药物。调查结果表明，诺华公司的行为是专利法领域的常见做法，而且没有证实上述非法限制竞争的迹象。因此，瑞士竞争委员会终止了调查。
该委员会在一份声明中表示，COMCO于2022年9月开始调查，以确定这家制药巨头是否打算通过提起各种专利侵权诉讼来非法保护其药品。该公司在声明中表示:“调查显示，诺华的行为最终成为专利法领域的惯例，此外，调查并未证实上述非法限制竞争的迹象。”
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.